Cytomegalovirus Infection Clinical Trial
Official title:
Phase IV.II Pilot Study of Treatment of Cytomegalovirus Infection With a Brief Induction With Ganciclovir i.v. Followed by Valganciclovir Oral in Solid Organ Transplant Patients.
The objectives of this study were:
1. To demonstrate the efficacy/safety of a short therapeutic strategy of treatment of CMV
infection/disease in SOT patients (kidney, liver and heart recipients) based on 21 days
of treatment.
2. To compare the exposure to ganciclovir, at steady state, after oral valganciclovir with
respect to ganciclovir given intravenously (i.v.).
3. Evaluate the security of this treatment with valganciclovir.
SOT recipients (kidney, liver and heart transplant) presenting CMV infection or disease were
eligible for inclusion if they were ≥18 years of age and presented a positive CMV
antigenemia (pp65) defined as ≥ 20positive cells/105 peripherical blood mononuclear cells
(PBMC). Patients excluded were those with severe CMV tissue invasive disease, unable to
receive oral medication, absolute neutrophil counts less than 500/ mm3, platelets <25000
platelets/mm3, Hemoglobin< 80g/l or estimated glomerular filtration rate< 10 mL/min
(according to the Cockcroft-Gault formula).
Patients received a short induction treatment with ganciclovir i.v (Cymevene®; F.
Hoffmann-La Roche Ltd, Basel, Switzerland) at the dose of 5 mg/kg/12h, by a peripherical
vein infusion of one hour, during 5 days followed by treatment with oral valganciclovir
(Valcyte®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 900 mg/12h during 16 days, after
meals, until complete a total of 21 days of treatment. In patients with impaired renal
function ganciclovir i.v. and oral valganciclovir doses were adjusted at each visit
according to estimated Glomerular Filtration Rate (GFR) by Cockcroft-Gault equation, as
recommended by the manufacturer.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00023036 -
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
|
||
| Terminated |
NCT01037712 -
In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir
|
Phase 4 | |
| Completed |
NCT00370006 -
Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM
|
Phase 1 | |
| Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
| Completed |
NCT01552369 -
CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
|
Phase 4 | |
| Completed |
NCT00223925 -
Maribavir for Prevention of CMV After Stem Cell Transplants
|
Phase 2 | |
| Active, not recruiting |
NCT05085366 -
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
|
Phase 3 | |
| Completed |
NCT01220895 -
Alternate Donor Study of Pre-Emptive Cellular Therapy
|
Phase 2 | |
| Completed |
NCT00942305 -
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
|
Phase 2 | |
| Completed |
NCT00373412 -
Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge
|
Phase 1 | |
| Completed |
NCT05105048 -
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647
|
Phase 1 | |
| Completed |
NCT00386412 -
TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant
|
Phase 2 | |
| Completed |
NCT03382405 -
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
|
Phase 1 | |
| Completed |
NCT02454699 -
Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT03910478 -
Dried Blood Spot Testing of CMV Detection in HCT Recipients
|
N/A | |
| Completed |
NCT01354301 -
Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
|
Phase 4 | |
| Active, not recruiting |
NCT01473849 -
Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients
|
N/A | |
| Completed |
NCT00880789 -
Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus
|
Phase 1 | |
| Completed |
NCT00817908 -
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
|
N/A | |
| Completed |
NCT00273143 -
A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients.
|
Phase 1 |